Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation.
BACKGROUND
One blood system for PLTs (INTERCEPT, Baxter Transfusion Therapies) is based on photochemical treatment (PCT) with small molecules that target cross-link nucleic acids (Helinx technology, Cerus Corp.) with amotosalen-HCl (S-59) and UVA light (320-400 nm) to inactivate pathogens and WBCs.


METHODS
A two-arm in vitro study was conducted to compare pooled buffy-coat-derived PLT concentrates (PCs) treated with the INTERCEPT blood system, resuspended in PLT additive solution (PAS) III (InterSol, Baxter Transfusion Therapies), and stored for up to 7 days (test units, n = 20) with unpaired, nontreated PCs, resuspended in PAS II (T-Sol, Baxter Transfusion Therapies), and prepared at the same center in the same manner (control units, n = 18).


RESULTS
PLT dose (x 1011/unit +/- SD) on Day 1 immediately following PCT was 3.0 +/- 0.4 for test units and 3.2 +/- 0.4 for control units. After 7 days of storage, the pH of all test units was maintained above 6.8. No marked trend was observed in the hypotonic shock response (HSR). Values among study groups were similar at the end of observation period: 68 +/- 11 percent for control unites versus 67 +/- 8 percent for test units (p > 0.05). Aggregation response to ristocetin was slightly lower in test units: at Day 7, 65 +/- 10 percent versus 76 +/- 6 percent (p < 0.05). Significantly higher (p < 0.001) glucose consumption, lactate production, and CD62P expression were observed in test units.


CONCLUSIONS
Compared to nontreated PLTs, the PCT process was associated with a variety of differences of in vitro analyses. Although significant, these changes were relatively small in most cases. Characteristics correlated with survival in vivo such as HSR and swirling were comparable between both study groups, indicating that the viability of the majority of cells appears to have persisted throughout 7 days of storage. The impact of this finding, however, remains to be investigated in clinical trials performed with 7-day stored PLTs.
Picker
Susanne M
SM
Transfusion Medicine, University of Cologne, Joseph Stelzmann Strasse 9, 50924 Cologne, Germany. suzanne.picker@medizin.uni-koeln.de
Speer
Relindis
R
Gathof
Birgit S
BS
D001424:Bacterial Infections / Q000517:prevention & control*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism*; D001793:Blood Preservation; D002245:Carbon Dioxide / Q000032:analysis; D002470:Cell Survival / Q000187:drug effects; D011564:Furocoumarins; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D009997:Osmotic Pressure; D010100:Oxygen / Q000032:analysis; D010777:Photochemistry; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count
D011564:Furocoumarins; D002245:Carbon Dioxide; D007770:L-Lactate Dehydrogenase; D005947:Glucose; C118577:amotosalen; D010100:Oxygen